“Small Molecule Activator of Sirtuin-1 Delays Onset of Nondiabetic FSGS in Animal Model”

https://pubmed.ncbi.nlm.nih.gov/38114708

The study suggests that activating sirtuin-1 with a small molecule activator can delay the onset of nondiabetic focal segmental glomerulosclerosis (FSGS) in an animal model by attenuating glomerulosclerosis progression and preventing transcription factor Wilms tumor 1 (WT1) downregulation, indicating that SIRT1 and claudin-1 are relevant for the pathophysiology of nondiabetic FSGS.